PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathway
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathway
Authors
Keywords
Ovarian cancer, PARP inhibitor, Resistance, Targeted therapy, ATR, CHK1
Journal
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
Volume 1876, Issue 2, Pages 188633
Publisher
Elsevier BV
Online
2021-10-05
DOI
10.1016/j.bbcan.2021.188633
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Overcoming PARPi resistance: preclinical and clinical evidence in ovarian cancer
- (2021) M. Chiappa et al. DRUG RESISTANCE UPDATES
- RNF168 regulates R-loop resolution and genomic stability in BRCA1/2-deficient tumors
- (2021) Parasvi S. Patel et al. JOURNAL OF CLINICAL INVESTIGATION
- Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer
- (2021) Lukas Gorecki et al. Cancers
- C/EBPβ promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer
- (2021) Jiahong Tan et al. ONCOGENE
- Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
- (2021) Elizabeth M. Swisher et al. Nature Communications
- EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition
- (2020) Sergey Karakashev et al. CANCER CELL
- Divergent metabolic responses dictate vulnerability to NAMPT inhibition in ovarian cancer
- (2020) Kei Kudo et al. FEBS LETTERS
- Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor
- (2020) Chunyan Xue et al. GYNECOLOGIC ONCOLOGY
- Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma
- (2020) Hisamitsu Takaya et al. Scientific Reports
- Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study
- (2020) Erika J Lampert et al. CLINICAL CANCER RESEARCH
- EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression
- (2020) Stephanie Lheureux et al. CLINICAL CANCER RESEARCH
- Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors
- (2020) Álvaro Lahiguera et al. EMBO Molecular Medicine
- Mechanisms of Multidrug Resistance in Cancer Chemotherapy
- (2020) Karol Bukowski et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature
- (2020) Erfan Aref-Eshghi et al. JOURNAL OF HUMAN GENETICS
- CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
- (2020) Elaine Sanij et al. Nature Communications
- Novel Therapeutic Strategies for Ovarian Cancer Stem Cells
- (2020) Nastassja Terraneo et al. Frontiers in Oncology
- The forefront of ovarian cancer therapy: update on PARP inhibitors
- (2020) M.R. Mirza et al. ANNALS OF ONCOLOGY
- Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer
- (2020) Tzu-Ting Huang et al. CANCER TREATMENT REVIEWS
- PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline
- (2020) William P. Tew et al. JOURNAL OF CLINICAL ONCOLOGY
- PARP inhibitor resistance: the underlying mechanisms and clinical implications
- (2020) He Li et al. Molecular Cancer
- Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches
- (2020) Innocenza Palaia et al. OncoTargets and Therapy
- Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
- (2020) Hyoung Kim et al. Nature Communications
- Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers
- (2020) Timothy A. Yap et al. Cancer Discovery
- Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
- (2020) Michelle McMullen et al. Cancers
- Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells
- (2020) Miriam K. Gomez et al. Cancers
- Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
- (2020) Florent Peyraud et al. Cancers
- A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance
- (2020) L. Tobalina et al. ANNALS OF ONCOLOGY
- FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer
- (2020) Shaily Arora et al. ONCOLOGIST
- Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
- (2020) Chang Yang et al. Frontiers in Immunology
- Newly diagnosed ovarian cancer: Which first-line treatment?
- (2020) Domenica Lorusso et al. CANCER TREATMENT REVIEWS
- Human CST complex protects stalled replication forks by directly blocking MRE11 degradation of nascent‐strand DNA
- (2020) Xinxing Lyu et al. EMBO JOURNAL
- Identification of regulators of poly-ADP-ribose polymerase inhibitor response through complementary CRISPR knockout and activation screens
- (2020) Kristen E. Clements et al. Nature Communications
- Immunotherapy Advances for Epithelial Ovarian Cancer
- (2020) Erin G. Hartnett et al. Cancers
- Advances in understanding DNA processing and protection at stalled replication forks
- (2019) Kimberly Rickman et al. JOURNAL OF CELL BIOLOGY
- Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
- (2019) Zebin Wang et al. Scientific Reports
- Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer
- (2019) Elizabeth L. Christie et al. Nature Communications
- BRCA1 Haploinsufficiency Is Masked by RNF168-Mediated Chromatin Ubiquitylation
- (2019) Dali Zong et al. MOLECULAR CELL
- Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition
- (2019) Rashid Gabbasov et al. CANCER BIOLOGY & THERAPY
- 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer
- (2019) Rachel M. Hurley et al. GYNECOLOGIC ONCOLOGY
- Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand
- (2019) Lin Mei et al. Journal of Hematology & Oncology
- Targeting dePARylation selectively suppresses DNA repair–defective and PARP inhibitor–resistant malignancies
- (2019) Shih-Hsun Chen et al. Science Advances
- A decade of clinical development of PARP inhibitors in perspective
- (2019) J Mateo et al. ANNALS OF ONCOLOGY
- Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality
- (2019) Ewa Gogola et al. CANCER CELL
- Ovarian Cancer Immunotherapy: Turning up the Heat
- (2019) Eleonora Ghisoni et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Activation of Wnt signaling promotes olaparib resistant ovarian cancer
- (2019) Tomomi M. Yamamoto et al. MOLECULAR CARCINOGENESIS
- Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma
- (2019) Panagiotis A. Konstantinopoulos et al. JAMA Oncology
- The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
- (2019) Kalindi Parmar et al. CLINICAL CANCER RESEARCH
- NAD+ consumption by PARP1 in response to DNA damage triggers metabolic shift critical for damaged cell survival
- (2019) Michael M. Murata et al. MOLECULAR BIOLOGY OF THE CELL
- ALDH1A1 contributes to PARP inhibitor resistance via enhancing DNA repair in BRCA2-/- ovarian cancer cells
- (2019) Lu Liu et al. MOLECULAR CANCER THERAPEUTICS
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2019) Antonio González-Martín et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ovarian cancer: Current status and strategies for improving therapeutic outcomes
- (2019) Ashwin Chandra et al. Cancer Medicine
- Heat Shock Proteins and Ovarian Cancer: Important Roles and Therapeutic Opportunities
- (2019) Abdullah Hoter et al. Cancers
- 1190PDPhase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)
- (2019) Y Drew et al. ANNALS OF ONCOLOGY
- Hopes and failures in front-line ovarian cancer therapy
- (2019) Irina Tsibulak et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response
- (2019) Elisena Franzese et al. Frontiers in Oncology
- NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer
- (2019) Timothy Nacarelli et al. CANCER RESEARCH
- Advanced technological tools to study multidrug resistance in cancer
- (2019) Luca Andrei et al. DRUG RESISTANCE UPDATES
- The Enigmatic Function of PARP1: From PARylation Activity to PAR Readers
- (2019) Tatiana Kamaletdinova et al. Cells
- The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others
- (2018) Ying Chen et al. BIOMEDICINE & PHARMACOTHERAPY
- Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma
- (2018) Sarah S. Bernards et al. GYNECOLOGIC ONCOLOGY
- A PET imaging agent for evaluating PARP-1 expression in ovarian cancer
- (2018) Mehran Makvandi et al. JOURNAL OF CLINICAL INVESTIGATION
- Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells
- (2018) Harveer Dev et al. NATURE CELL BIOLOGY
- RPA and RAD51: fork reversal, fork protection, and genome stability
- (2018) Kamakoti P. Bhat et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity
- (2018) Sergey Karakashev et al. Nature Communications
- PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation
- (2018) George E. Ronson et al. Nature Communications
- Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
- (2018) Stephen J. Pettitt et al. Nature Communications
- RPA and RAD51: fork reversal, fork protection, and genome stability
- (2018) Kamakoti P. Bhat et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer
- (2018) Verena Wieser et al. Oncotarget
- Mechanisms for stalled replication fork stabilization: new targets for synthetic lethality strategies in cancer treatments
- (2018) Hongwei Liao et al. EMBO REPORTS
- 53BP1–RIF1–shieldin counteracts DSB resection through CST- and Polα-dependent fill-in
- (2018) Zachary Mirman et al. NATURE
- Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
- (2018) Olga Kondrashova et al. Nature Communications
- Prediction of DNA Repair Inhibitor Response in Short Term Patient-Derived Ovarian Cancer Organoids
- (2018) Sarah J. Hill et al. Cancer Discovery
- Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials
- (2018) Emily Hinchcliff et al. GYNECOLOGIC ONCOLOGY
- DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells
- (2018) Yizhou Joseph He et al. NATURE
- BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
- (2018) Kevin K Lin et al. Cancer Discovery
- PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
- (2018) Liya Ding et al. Cell Reports
- Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response
- (2018) Paola Francica et al. Genome Medicine
- RAD-ical New Insights into RAD51 Regulation
- (2018) Meghan R. Sullivan et al. Genes
- PARP inhibitors in ovarian cancer
- (2018) Elisena Franzese et al. CANCER TREATMENT REVIEWS
- ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells
- (2017) Stephanie A. Yazinski et al. GENES & DEVELOPMENT
- Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach
- (2017) et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The Role of PALB2 in the DNA Damage Response and Cancer Predisposition
- (2017) Thales Nepomuceno et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- Restoration of Replication Fork Stability in BRCA1- and BRCA2-Deficient Cells by Inactivation of SNF2-Family Fork Remodelers
- (2017) Angelo Taglialatela et al. MOLECULAR CELL
- RADX Promotes Genome Stability and Modulates Chemosensitivity by Regulating RAD51 at Replication Forks
- (2017) Huzefa Dungrawala et al. MOLECULAR CELL
- ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response
- (2017) Andrew N. Blackford et al. MOLECULAR CELL
- EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation
- (2017) Beatrice Rondinelli et al. NATURE CELL BIOLOGY
- Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers
- (2017) Chaoyang Sun et al. Science Translational Medicine
- Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
- (2017) Olga Kondrashova et al. Cancer Discovery
- Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer
- (2017) Ethan Brill et al. Oncotarget
- A PALB2-interacting domain in RNF168 couples homologous recombination to DNA break-induced chromatin ubiquitylation
- (2017) Martijn S Luijsterburg et al. eLife
- ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells
- (2016) Aparajitha Vaidyanathan et al. BRITISH JOURNAL OF CANCER
- Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and aBRCAmutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy
- (2016) Ursula A. Matulonis et al. CANCER
- The BRCA1- 11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin
- (2016) Y. Wang et al. CANCER RESEARCH
- A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy
- (2016) M. Makvandi et al. CANCER RESEARCH
- The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models
- (2016) L. Oplustil O'Connor et al. CANCER RESEARCH
- Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib
- (2016) Aiste McCormick et al. CLINICAL CANCER RESEARCH
- Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA -Mutant Ovarian Cancer Models
- (2016) Hyoung Kim et al. CLINICAL CANCER RESEARCH
- Homologous recombination deficiency and ovarian cancer
- (2016) Jonathan A. Ledermann et al. EUROPEAN JOURNAL OF CANCER
- Replication fork stability confers chemoresistance in BRCA-deficient cells
- (2016) Arnab Ray Chaudhuri et al. NATURE
- Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1 -Mutant Ovarian Cancer
- (2016) Young Eun Choi et al. Cell Reports
- Targeting DNA Replication Stress for Cancer Therapy
- (2016) Jun Zhang et al. Genes
- Structure and function of the telomeric CST complex
- (2016) Cory Rice et al. Computational and Structural Biotechnology Journal
- Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing
- (2016) Alexander J. Cole et al. Scientific Reports
- Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population
- (2015) Honglin Song et al. JOURNAL OF CLINICAL ONCOLOGY
- Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
- (2015) Amit M Oza et al. LANCET ONCOLOGY
- Whole–genome characterization of chemoresistant ovarian cancer
- (2015) Ann-Marie Patch et al. NATURE
- Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells
- (2015) Young Eun Choi et al. Oncotarget
- PARP Inhibitors as P-glyoprotein Substrates
- (2014) Denise Lawlor et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Mechanisms and principles of homology search during recombination
- (2014) Jörg Renkawitz et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699)
- (2014) Selvi Durmus et al. PHARMACEUTICAL RESEARCH
- ATR phosphorylates SMARCAL1 to prevent replication fork collapse
- (2013) F. B. Couch et al. GENES & DEVELOPMENT
- Causes and consequences of replication stress
- (2013) Michelle K. Zeman et al. NATURE CELL BIOLOGY
- Double-strand break repair: 53BP1 comes into focus
- (2013) Stephanie Panier et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells
- (2012) Ilirjana Bajrami et al. EMBO Molecular Medicine
- Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor
- (2012) Louise J Barber et al. JOURNAL OF PATHOLOGY
- Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
- (2012) Janneke E. Jaspers et al. Cancer Discovery
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started